ORIGINAL RESEARCH

A model of secreting murine mammary epithelial HC11 cells comprising endogenous Bcrp/Abcg2 expression and function

Jonas Tallkvist • Yagmur Yagdiran • Louise Danielsson • Agneta Oskarsson

Received: 12 December 2014 / Accepted: 9 March 2015 / Published online: 20 March 2015 © Springer Science+Business Media Dordrecht 2015

Abstract Breast cancer resistance protein (Bcrp/Abcg2) and multidrug transporter 1 (Mdr1/Abcb1) are efflux proteins located in the apical membrane of mammary epithelial cells (MEC). Bcrp is induced in MEC during gestation and lactation, while Mdr1 is down-regulated during lactation. Numerous drugs and toxic compounds are known to be actively secreted into milk by Bcrp, but most chemicals have not been investigated in this respect, emphasizing the need for functional Bcrp studies in an established cell line with secreting mammary epithelial cells. The present study was undertaken to examine expressions of Bcrp and Mdr1 in mammary epithelial HC11 cells, derived from a mid-gestational murine mammary gland. In addition, Bcrp function was assessed by transport experiments with mitoxantrone (MX) in undifferentiated HC11 cells, in HC11 cells subjected to Bcrp RNA interference (RNAi), as well as in HC11 cells stimulated to differentiate by treatment with lactogenic hormones. Differentiated HC11 cells organized into alveolarresembling structures and gene expression of the major milk protein β-casein was induced, whereas undifferentiated cells formed monolayers with lower β-casein expression. Bcrp and Mdr1 gene and protein were expressed in both undifferentiated and differentiated HC11 cells. Differentiation of HC11 cells resulted in increased Bcrp protein expression, while Mdr1 gene and protein expressions were reduced. The Bcrp inhibitor elacridar (GF120918) reduced secretion and increased accumulation of MX in both undifferentiated and differentiated HC11 cells. Silencing of the *Bcrp* gene caused an increased accumulation of MX. The results indicate that the HC11 cell model provides a promising tool to investigate transport of potential Bcrp substrates in mammary epithelial cells.

Keywords Active transport \cdot BCRP \cdot Mammary epithelial HC11 cells \cdot Mdr1 \cdot Mitoxantrone \cdot RNAi

Introduction

Breast cancer resistance protein (BCRP/ABCG2) is a 7kDa protein, composed by a single N-terminal ATP binding site followed by six putative transmembrane segments, belonging to the ATP binding cassette (ABC) superfamily of transporters (Doyle et al. 1998). BCRP is situated in the apical membrane of epithelial cells in numerous tissues including the intestine, liver, kidneys, and several blood-tissue barriers where it serves to extrude its substrates and by these means limiting availability and systemic exposure (Jonker et al. 2000; Maliepaard et al. 2001; Zhang et al. 2004). Furthermore, BCRP is highly expressed in cancer cells where it prevents the uptake of the antineoplastic drug mitoxantrone, diminishing its therapeutic effect (Doyle et al. 1998; Bates et al. 2001). Thus, one important biological function of BCRP in most tissues appears to comprise cellular protection and detoxification.

J. Tallkvist (⊠) · Y. Yagdiran · L. Danielsson · A. Oskarsson Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden e-mail: Jonas.Tallkvist@slu.se

BCRP is also expressed in apical membrane of mammary epithelial cells (MEC) which faces the alveolar lumen of the mammary glands (Jonker et al. 2005; Lindner et al. 2013). During gestation and lactation, BCRP is up-regulated. Although the physiological role for BCRP in MEC is not totally clarified, the transporter has been demonstrated to actively efflux vitamin B_2 (riboflavin) into milk (van Herwaarden et al. 2007; Vlaming et al. 2009). Furthermore, active secretion of a variety of exogenous BCRP substrates, including human and veterinary drugs, environmental pollutants, and other food contaminants, into milk has been demonstrated (Jonker et al. 2005; van Herwaarden et al. 2007; Mealey 2012). Expression and function of BCRP can also be influenced by chemicals. Thus, flavonoids and isoflavonoids, present in many food and feed plants, inhibit BCRP and may thus decrease milk secretion of BCRP substrates (Zhang et al. 2004; Morris and Zhang 2006). On the other hand, 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD) and the fungicide prochloraz induce BCRP in mammary epithelial cells and may increase the milk excretion of BCRP substrates (Halwachs et al. 2013).

The exposure of hazardous compounds via milk in sensitive population groups is of high concern in risk assessment and there is a need for methods to screen for chemicals with active transport into milk and to further investigate the underlying mechanisms. Transfected Madin-Darby Canine Kidney II (MDCKII) epithelial cells stably expressing human, bovine, and caprine BCRP have been used to identify new BCRP substrates as well as the impact of the common Y581S point mutation in BCRP function (Jonker et al. 2000; Real et al. 2011; Wassermann et al. 2013; Halwachs et al. 2014). However, expression and function of endogenous BCRP in non-tumorigenic mammary epithelial cell lines have not yet been examined. Such a model would be valuable for studies on BCRP expression and function after treatment with xenobiotics.

HC11 cells are non-tumorigenic mammary epithelial cells derived from the mouse mammary epithelial cell line COMMA-1D collected from the mammary glands of Balb/c mice during mid-gestation (Danielsson et al. 1984). The HC11 cells express functional prolactin receptors and have been used as a model to examine the progression of mammary epithelial differentiation to a secreting phenotype (Ball et al. 1988; Marte et al. 1994; Desrivières et al. 2003). In addition, the HC11 cell model has been applied to characterize transporters implicated in the flux of zinc, copper, sodium, and calcium across the membranes of the lactating mammary epithelium (Kelleher and Lönnerdal 2005, 2006; Boyd and Náray-Fejes-Tóth 2007; Öhrvik et al. 2010; McCormick and Kelleher 2012; Ross et al. 2013). However, no studies have so far been directed to investigating expression and function of ABC transporters in HC11 cells.

The present study was undertaken to examine endogenous expressions of Bcrp and Mdr1 in mammary epithelial HC11 cells. In addition, transport experiments with the BCRP substrate mitoxantrone (MX) were carried out in undifferentiated HC11 cells, in HC11 cells subjected to *Bcrp* RNAi, as well as in HC11 cells stimulated to differentiate by treatment with lactogenic hormones.

Materials and methods

Cells

HC11 cells of passage 26 were a generous gift from Dr Shannon Kelleher, Department of Nutritional Sciences, Pennsylvania State University, USA, and was cultured by permission of Dr Bernd Groner, Institute for Biomedical Research, Frankfurt, Germany. The cells were expanded in T75 tissue culture flasks at 37 °C in 15 ml of sterile filtered RPMI 1640 medium containing Lglutamine and 25 mM HEPES (Invitrogen) supplemented with 50 µg/ml gentamicin, 5 µg/ml bovine insulin, 10 ng/ml epidermal growth factor (EGF), 7.5 % NaHCO₃, and 10 % heat-inactivated fetal bovine serum (FBS) in an atmosphere of 95 % air and 5 % CO₂ in 95 % relative humidity. The cell culture medium was changed every 2-3 days and cells between passages 28-33 were harvested at 80-90 % confluency. HC11 cells were seeded at a density of 50,000 cells/cm² in six-well plates and cultured to confluency. Two days postconfluency, cells were cultured for an additional 24 h in the FBS-containing RPMI 1640 medium described above but without EGF. Differentiation of the HC11 cells was then achieved by culturing the cells for 72 h in EGF- and FBS-free RPMI 1640 medium supplemented with 1 µg/ml prolactin and 1 µM cortisol as described (Desrivières et al. 2003). Undifferentiated HC11 cells (controls) were cultured in parallel with the FBS- and EGF-containing RPMI 1640 medium. To study the cellular organization, approximately 800,000

cells in a volume of 400 µl were seeded per chamber on slides (Lab-Tec[®] chamber slideTM system, Nalge Nunc International). In four of the eight chambers on each slide (n=3), the cells were allowed to differentiate for 3 days as described above whereas the other four served as undifferentiated controls. The cells were fixed in 4 °C acetone for 5 min and then rinsed with 1× PBS, pH 7.4, prior to nuclei staining with hematoxylin.

Quantitative real-time RT-PCR

Following incubation of the HC11 cells in either control or differentiating culture medium as described above or transfection medium as described below, the cells were rinsed with $1 \times PBS$ and the RNA was isolated by applying NucleoSpin®RNA II Columns with DNaseI according to the instructions of the manufacturer (BD Biosciences). As a quality control of primers used in the real-time RT-PCR with cellular RNA, primers were tested on RNA from mouse mammary gland tissues taken at different lactation stages. HARLAN NMRI mice were given a standard pellet diet and tap water ad libitum under standard conditions of temperature and light. Animals were killed by cervical dislocation and mammary glands from pregnant (gestation days 13 and 18), lactating (lactation days 2 and 9), and weaning (weaning day 2) mice were rapidly excised, placed in RNA later (Invitrogen), snap-frozen in liquid nitrogen, and stored at -70 °C pending isolation of total RNA. Tissues were homogenized in 10 volumes of RA1 buffer as recommended by the manufacturer (BD Biosciences) and RNA isolated with NucleoSpin®RNA II Columns with DNaseI as described above. Animal experiments were ethically approved (permit no. 2012-15-2934-00587) and carried out in collaboration with Dr Christopher Knight, at the Department of Health and Medical Sciences, University of Copenhagen, Denmark. Total RNA from mammary glands was quantitated by use of the RiboGreen protocol with DNase I (Invitrogen) and RNA samples were stored at -70 °C until used. Quantitative gene expression was measured by real-time RT-PCR by applying a Rotorgene, RG3000 (Corbett Research), as described (Öhrvik et al. 2010) in the presence of 400 nM forward and reverse primers in a total volume of 12.5 μ l (Table 1).

 Table 1
 Exon-spanning oligonucleotide primers used for quantitative gene expression analyses by real-time RT-PCR

Gene	Primer sequences
β-Casein	5'-CTTAACCCCACCGTCCAAT-3' (forward) 5'-AGCATGATCCAAAGGTGAAAA-3' (reverse)
Bcrp/Abcg2	5'-CGCAGAAGGAGATGTGTT-3' (forward) 5'-TTGGATCTTTCCTTGCTGCT-3' (reverse)
Mdr1/Abcb1	5'-GCTGTTAAGGAAGCCAATGC-3' (forward) 5'-AGCAATGGCGATTCTCTGGTT-3' (reverse)
Cyclophilin B	5'-GCGCAATATGAAGGTGCTCT-3' (forward) 5'-GAAGTCTCCACCCTGGATCA-3' (reverse)

Western blot

HC11 cells were seeded at a density of 50,000 cells/cm² in a total of four separate T75 tissue culture flasks and cultured and differentiated as described above prior to harvesting by trypzination and homogenization of the obtained cell pellet in five volumes of RIPA-lysis buffer. HC11 cells in two T75 flasks were differentiated as described above while the cells in the other two flasks served as undifferentiated controls. The homogenization of the HC11 cells was carried out in 1.5 ml Eppendorf tubes by thorough pipetting. Homogenates were incubated on ice for 30 min and then centrifuged at $16,000 \times g$ for 30 min at 4 °C and supernatant protein concentrations determined as described (McKie et al. 2000). Twenty to 50 µg of cellular protein was separated on a 10 % Tris-Glycine polyacrylamide gel under reducing conditions and blotted to nitrocellulose as described (Öhrvik et al. 2007). Three nitrocellulose membranes with proteins from each T75 flasks were incubated in blocking buffer (5 % nonfat dry milk powder in Tris-buffered saline containing 0.05 % Tween 20 (TBS-T)) overnight at 4 °C. Membranes were then hybridized with a primary BCRP antibody (BXP-53, Abcam) diluted 1:100 or primary MDR1 antibody (JSB-1, Abcam) diluted 1:200 in TBS-T. The primary antibodies were detected by Horse Radish Peroxidase-conjugated secondary antibodies (ab6728, Abcam) diluted 1:7,500 in TBS-T. In order to normalize the intensities of the bands, all the membranes were stripped at 60 °C with buffer containing 62.5 mM Tris-HCl, 100 mM 2mercaptoethanol, and 2 % SDS, and then hybridized with anti-tubulin antibody (YOL1/34) diluted 1:3,000. Horse Radish Peroxidase-conjugated secondary antibodies to tubulin (ab6734, Abcam) diluted 1:5,000 in

TBS-T. HRP was detected by ECL Advance (GE Healthcare) and the intensities of the obtained bands quantitated as described (Öhrvik et al. 2010). As a quality control of the antibodies used in the Western with cellular protein, they were tested on protein isolated from mammary gland of pregnant and lactating mice.

Bcrp RNAi

Prior to the Bcrp RNAi of the HC11 cells, optimization of transfection efficiency was performed by incubating various densities of HC11 cells with either siTOX Transfection Control (Dharmacon) or a non-targeting negative control (On-Target plus siControl Non-Targeting Pool, Dharmacon) in the presence of various dilutions of DharmaFECT siRNA Transfection Reagents 1-4, as recommended by the manufacturer (Dharmacon). ATP levels were measured to check viability of the HC11 cells following each set of transfection condition by applying the ATP Determination Kit (Invitrogen), with formaldehyde-treated cells as positive controls. Firefly luciferase induced chemiluminescence of cellular ATP was measured on a Victor² 1420 multilabel counter (PerkinElmer). Following the various transfection conditions, the one resulting in the lowest viability following treatment with siTOX Transfection Control reagent and the highest viability following treatment with the On-Target plus siControl Non-Targeting Pool was selected. Following this optimization of transfection efficiency, cyclophilin B siRNA transfection was performed under the optimized condition by the use of siControl cyclophilin B siRNA (targeting mouse cyclophilin, accession number NM 011149) according to the instructions of the manufacturer. The silencing of the cyclophilin B gene was measured by quantitative real-time RT-PCR with specific primers (Table 1) as described above. After successful silencing of cyclophilin B, the optimized siRNA transfection protocol was adopted to silence Bcrp expression. HC11 cells were harvested in antibiotic-free RPMI 1640 medium and seeded into six-well tissue culture plates at a density of 8,300 cells/cm². After incubation for 24 h at 37 °C, the medium was replaced with 2 ml of transfection medium (Opti-MEM) containing 100 nM On-Target plus SMART pool (targeting mouse BCRP, accession number NM 011920) and DharmaFECT 1 Transfection Reagent diluted 1:4. Mock-transfected cells were incubated as described above with 2 ml Opti-MEM containing 100 nM On-Target plus siControl Non-Targeting RNA duplexes. Following transfection for 48 h at 37 °C, the HC11 cells were either subjected to RNA isolation for quantitative gene expression of *Bcrp* by real-time RT-PCR or transport experiments with MX (as described below).

Transport experiments

Prior to the experiments, HC11 cells were seeded in 12well plates at a density of 50,000 cells/cm² and cultured and treated as described above. MX (Sigma) was used to examine the function of BCRP in the HC11 cells using ³H-MX, with a specific radioactivity of 4 Ci/mmol, as tracer (Moravek Biochemicals). It has previously been demonstrated that BCRP-mediated transport of MX is reduced by GF120918 (de Bruin et al. 1999). Accumulation studies with MX were performed as follows. HC11 cells were rinsed with 2×1.5 ml of 37 °C Hank's Balanced Salt Solution with CaCl₂ and MgCl₂ (Invitrogen), pH 7.4, containing 25 mM N-(2hydroxyehtyl) piperazine-N'-(2-ethanesulfonic) acid (HEPES, Sigma-Aldrich) (HBSS) and then preincubated for 30 min at 37 °C in 1.5 ml HBSS. After pre-incubation, the HC11 cells were incubated at 37 °C for 60 min with 37 °C HBSS containing 1 µM MX supplemented with 3,000 Bq ³H-MX/ml. Experiments including inhibitor were performed in HBSS, containing 1 µM of GF120918 during the 60-min incubation period. At the end of the experiment, the HC11 cells were rinsed with 3×1.5 ml ice-cold HBSS and thereafter lysed by adding 1 ml 0.5 M NaOH to each well. The MX concentration in the HC11 cells was then calculated from the radioactivity measurement by β -spectrometry using a 1900 CA Tri-Carb®Liquid Scintillation Analyzer (Packard Instruments). An aliquot of the cell lysate was used for protein determination by applying the BCA method (as described above).

To study secretion of MX, HC11 cells were preincubated as described above and then incubated with 1 μ M MX supplemented with 3,000 Bq ³H-MX/ml at 37 °C for 60 min. After this loading period, the incubation medium was discarded and the HC11 cells were rinsed with 2×1.5 ml 37 °C HBSS. After the washes, 1.5 ml of 37 °C HBSS with or without 1 μ M GF120918 was added to the wells followed by incubation at 37 °C for 45 min. At the end of the secretion experiment, the HBSS was sampled and MX concentrations measured by β -spectrometry as described above. Both accumulation and secretion of MX were normalized to total cellular protein of the HC11 cells. Prior to the transport experiments, potential cellular toxicity of the MX and GF120918 was assessed by measuring cellular ATP levels as described above or leakage of lactate dehydrogenase (LDH) as described previously (Aspenström-Fagerlund et al. 2007). No effects in ATP- or LDH levels were detected in the experimental conditions and MX and GF120918 concentrations used in the present study indicating that the observed effects in accumulation and secretion were not a result of cytotoxicity induced by of these chemical compounds.

Statistics

Statistical analysis was performed using Statview 4.1 software for PC. Kruskal-Wallis was used to detect any significant differences in the data. Mann–Whitney was applied to examine statistically significant differences between two groups. The level of significance was set at $p \le 0.05$.

Results

Cellular organization

The morphology of the HC11 cells was affected by the differentiation procedure. The differentiated cells showed a characteristic pattern with alveolar-resembling structures including lumina, whereas the undifferentiated cells were organized as a monolayer (Fig. 1a).

mRNA expressions

Gene expression of β -casein (*Csn2*) and *Bcrp* was detected in both undifferentiated and differentiated HC11 cells. A statistically significant induction of β -casein gene expression was observed in the differentiated HC11 cells as compared to the undifferentiated controls (Fig. 1b). Thus, the relative β -casein gene expression was increased twofold in the differentiated as compared to the undifferentiated HC11 cells (Fig. 1b). The relative *Bcrp* gene expression was at a similar level in undifferentiated and differentiated HC11 cells (Fig. 2a). A statistically significant twofold reduction in *Mdr1* gene expression was observed in the differentiated HC11 as compared to the undifferentiated ones (Fig. 2b).



Fig. 1 a Cellular organization of undifferentiated and differentiated HC11 cells as described in "Materials and methods." Undifferentiated HC11 cells not stimulated with lactogenic hormones are organized as monolayers (*left*). Differentiated cells treated with prolactin and hydrocortisone are formatted in alveolar-resembling structures with alveolar lumina (*right*). b Relative β -casein gene expression in undifferentiated and differentiated HC11 cells, as described in "Materials and methods." The data are presented as means±SD of six samples from two separate experiments. Statistically significant different as compared to undifferentiated controls, *p≤0.05

Protein expressions

Bcrp and Mdr1-protein was detected in both undifferentiated and differentiated HC11 cells (Fig. 3). Tubulinnormalized Bcrp protein expression was up-regulated and Mdr1 protein expression down-regulated in the differentiated as compared to the undifferentiated HC11 cells (Fig. 3). Quantification of Bcrp and Mdr1 protein levels in differentiated and undifferentiated HC11 cells as performed in two separate experiments with triplicate analyses did not show any overlaps in protein levels.



Fig. 2 Relative gene expression of *Bcrp* (a) and *Mdr1* (b) in undifferentiated and differentiated HC11 cells, as described in "Materials and methods." The data are presented as means \pm SD of six samples from two separate experiments. Statistically significant different as compared to undifferentiated controls, *p \leq 0.05

Bcrp silencing

To test the function of our optimized transfection efficiency conditions, RNAi was initially performed with the house-keeping gene cyclophilin B. Our results showed that almost a 90 % down-regulation of the cyclophilin B gene expression was obtained (Fig. 4). Using the same protocol with *Bcrp* siRNA duplexes, *Bcrp*-transcript levels were reduced to the same extent as cyclophilin (Fig. 4).

Transport experiments

The transport experiments with ³H-MX showed that the accumulation was increased in both undifferentiated and differentiated HC11 cells simultaneously incubated with GF120918 (Fig. 5a). Thus, in the presence of the BCRP inhibitor, the accumulation of MX increased with about 21 % in the undifferentiated HC11 cells and with about 36 % in the



Fig. 3 Protein expression of BCRP (a) and MDR1 (b) in undifferentiated and differentiated HC11 cells, normalized to tubulin expression as described in "Materials and methods." The data represent BCRP and MDR1 protein expression in HC11 cell lysates obtained in two separate experiments, each comprising three membranes per protein expressed as relative means and ranges

differentiated ones. Our results also showed that the accumulation of MX was higher in the differentiated HC11 cells as compared to the undifferentiated controls (Fig. 5a). The presence of the inhibitor GF120918 also resulted in a decreased secretion of MX from the loaded HC11 cells (Fig. 5b). The secretion of MX was reduced to about 65 % in the presence of GF120918 in undifferentiated HC11 cells and to about 70 % in the differentiated ones. The results obtained in the transport experiments with ³H-MX showed that the accumulation of MX in HC11 cells increased twofold by *Bcrp* RNAi as compared to the MX accumulation in the mocktransfected HC11 cells (Fig. 5a).



Fig. 4 Relative gene expressions of cyclophilin B and *Bcrp* in HC11 cells subjected to RNA interference (RNAi). The data are presented as means±SD of three to five samples obtained from two separate experiments. Statistically significant as compared to untransfected controls (Opti-MEM) and mock-transfected cells (Opti-MEM containing Lipid 1 diluted 1:4 and non-targeting RNA duplexes) as described in "Materials and methods," * $p \le 0.05$

Discussion

The results obtained in the present investigation demonstrate for the first time that both Bcrp and Mdr1 are expressed in the HC11 cells and are up- and downregulated, respectively, by differentiation as in mammary epithelial cells in vivo during lactation. Thus, whereas Bcrp protein levels were increased in HC11 cells differentiated into a secreting phenotype, Mdr1 protein levels were decreased. These results are in line with the in vivo findings that BCRP is up-regulated and MDR1 downregulated in lactating mammary glands in various species (Alcorn et al. 2002; Jonker et al. 2005; Gilchrist and Alcorn 2010) and suggest that the HC11 model can be used to both assess function of endogenous Bcrp and to detect new substrates as well as inducers and inhibitors of this transporter.

HC11 cells have been used as a model for studies on hormonal regulation of mammary epithelial cell differentiation as well as milk protein gene expression and secretion (Wartmann et al. 1996; Desrivières et al. 2003; Kabotyanski et al. 2006). Furthermore, HC11 cells have been applied to examine the impact of toxic compounds on lactating mammary cells (Öhrvik et al. 2010) and also to characterize some transporters belonging to the Solute Carrier (SLC) family and ion channels, which are implicated in the flux of magnesium, zinc, copper, and calcium across the membranes of the lactating mammary epithelium (Kelleher and





Fig. 5 Accumulation (a) and secretion (b) of ³H-mitoxantrone in undifferentiated (*No*) or differentiated (*Yes*) HC11 cells, treated with the BCRP inhibitor GF120918, and in mock-transfected (*mock*) and *Bcrp* RNAi treated (*Bcrp* RNAi) HC11 cells, as described in "Material and methods." The data are presented as means±SD of 6–12 samples and expressed as picomole mitoxantrone/milligram cellular protein as described in "Materials and methods." Statistically significant differences between groups are indicated by links between the columns (* $p \le 0.05$; * $p \le 0.01$)

Lönnerdal 2005, 2006; Boyd and Náray-Fejes-Tóth 2007; Öhrvik et al. 2010; Wolf et al. 2010; McCormick and Kelleher 2012; Ross et al. 2013). However, the HC11 cell model has not yet been used to characterize expression and/or function of ATP Binding Cassette (ABC) transporters. The localization of both BCRP and MDR1 in the apical membranes of MECs in combination with the promiscuity of these active transporters has risen considerable concern from public health, food safety, and regulatory perspectives about the presence of drugs and toxic compounds in milk both for breast-fed infants as well as for consumers of dairy products (Wassermann et al. 2013).

Herein, we showed that Bcrp gene expression was at a similar level in undifferentiated and differentiated HC11 cells whereas Mdr1 transcript levels were reduced in the differentiated ones. The reason for the lack of induction of Bcrp mRNA in the HC11 cells by lactogenic stimulation in the present investigation is unknown. However, one possible explanation may be that the HC11 cells originally derive from mammary tissue of BALB/c mice during gestation when Bcrp transcripts levels are induced to a stage where no further increases in gene expression occurs (Danielsson et al. 1984; Jonker et al. 2005). In support of this, silencing of Bcrp gene expression in undifferentiated HC11 cells resulted in a marked decrease in Bcrp function as assessed by increased MX accumulation, which probably would not have been possible to demonstrate if the endogenous Bcrp expression in the control cells was at a baseline level.

In the present investigation, the HC11 cells differentiated by treatment with prolactin and cortisol were organized into alveolar-like structures with lumina resembling the organization of the mammary epithelial cells observed in the mammary glands in vivo during lactation (Burgoyne and Duncan 1998; Richert et al. 2000). Beside the changes in cellular organization by lactogenic stimulation, β -casein gene expression was also induced in the HC11 cells. It has previously been demonstrated that β -case in responds to prolactin in HC11 cells (Ball et al. 1988) and that synthesis occurs in rodent MEC in vivo and that the abundance of this milk protein increases during gestation and peaks at mid-lactation (Robinson et al. 1995; Burgoyne and Duncan 1998; Richert et al. 2000; McManaman and Neville 2003). Thus, reorganization of HC11 cells into alveolar-resembling formations in combination with an increased β-casein gene expression by lactogenic stimulation appears to be reliable markers of a secreting phenotype. Based on the results obtained in the present study, reduced gene and protein expression of Mdr1 as well as increased expression of Bcrp protein may also be used as secretory markers of the HC11 cells.

Our results showed that the net accumulation of MX was higher in the differentiated HC11 cells as compared to the undifferentiated controls despite an apparent higher expression of Bcrp. This may, at least in part, be explained by a reduced expression of Mdr1. Although MX extrusion is predominantly mediated by

Bcrp, it has been demonstrated that MX can be transported to the extracellular compartment by Mdr1 although this transporter harbors less substrate specificity for MX than Bcrp and thus requires higher substrate concentrations (Ahmed-Belkacem et al. 2005; Rautio et al. 2006; Kodaira et al. 2010). Numerous SLC transporters, comprising both organic cation transporters (OCTs) and organic anion polypeptide transporters (OATPs), in MECs are affected at the transcriptional level by lactogenic stimulation (Alcorn et al. 2002; Gilchrist and Alcorn 2010) including some with potential MX affinity. It may, hence, be possible that the increased accumulation of MX in the HC11 cells featuring a secretory phenotype as opposed to the undifferentiated ones is not only connected to the reduced expression of Mdr1 observed herein but also to a concerted action of a number of other transporters including Oct or/and Oatp transporters.

Madine-Darby Canine Kidney II (MDCK II), human intestinal epithelial cells (Caco-2), human breast adenocarcinoma cells (MCF7), human choriocarcinoma cells (BeWo), and human bone osteosarcoma cells (SAOS-2) constitute examples of models used to characterize the function and substrate specificities of efflux proteins such as BCRP (Doyle et al. 1998; Jonker et al. 2000; Ceckova et al. 2006; Matsson et al. 2007; Li et al. 2011; Wassermann et al. 2013). However, cancer cell lines and non-tumorigenic cell lines deriving from tissues other than the alveolar lining of the mammary glands harbor different sets of transporter protein panels at both the apical and basolateral membranes which may affect secretion, and net accumulation of substrates may therefore differ (Krajci 2013). As expected by a Bcrp inhibitor, GF120918 treatment of HC11 cells decreased both net accumulation and secretion of MX. This corroborates our suggestion that the HC11 cells can be used for assessing transport of potential Bcrp substrates across the mammary epithelium.

The results obtained in the present investigation demonstrate for the first time that the murine mammary epithelial HC11 cells feature endogenous Bcrp and Mdr1 expression, and that the expressions of these transporter proteins appear to respond to treatment with lactogenic hormones in a corresponding manner as mammary epithelial cells in vivo during lactation. Based on these findings, it can be concluded that the HC11 cells comprise a promising tool to assess the impact of drugs and other chemicals on endogenous BCRP function. Acknowledgments This study was supported by the Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (Formas).

Conflict of interest There are no conflicts of interest regarding this manuscript and the authors have nothing to disclose.

References

- Ahmed-Belkacem A, Pozza A, Munoz-Martinez F, Bates SE, Castanys S, Gamarro F, et al. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res. 2005;65:4852–60.
- Alcorn J, Lu X, Moscow A, McNamara PJ. Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcriptionpolymerase chain reaction. J Pharmacol Exp Ther. 2002;303:487–96.
- Aspenström-Fagerlund B, Ring L, Aspenström P, Tallkvist J, Ilbäck NG, Glynn A. Oleic acid and docosahexanoic acid cause an increase in the paracellular absorption of hydrophilic compounds in an experimental model of human absorptive enterocytes. Toxicology. 2007;237: 12–23.
- Ball RK, Friis RR, Schoenenberger CA, Doppler W, Groner B. Prolactin regulation of β-casein gene expression and of a cytosolic 120-kD protein in a cloned mouse mammary epithelial cell line. EMBO J. 1988;7:2089–95.
- Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T. The role of half-transporters in multidrug resistance. J Bioenerg Biomembr. 2001;33:503–11.
- Boyd C, Náray-Fejes-Tóth A. Steroid-mediated regulation of the epithelial sodium channel subunits in mammary epithelial cells. Endocrinology. 2007;148:3958–67.
- Burgoyne RD, Duncan JS. Secretion of milk proteins. J Mammary Gland Biol Neoplasia. 1998;3:275–86.
- Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, et al. Expression and functional activity of breast cancer resistance protein (BCRP/ABCG2) transporter in the human choriocarcinoma cell line BeWo. Clin Exp Pharmacol Physiol. 2006;33:58–65.
- Danielsson KG, Oborn CJ, Durban EM, Butel JS, Medina D. Epithelial mouse mammary cell line exhibiting normal morphogenesis in vivo and functional differentiation in vitro. Proc Natl Acad Sci U S A. 1984;81:3756–60.
- de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 1999;146:117–28.
- Desrivières S, Prinz T, Castro-Palomino Laria N, Meyer M, Boehm G, Bauer U, et al. Comparative proteomic analysis of proliferating and functionally differentiated mammary epithelial cells. Mol Cell Proteomics. 2003;2:1039–54.
- Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. PNAS USA. 1998;95:15665–70.

- Gilchrist SE, Alcom J. Lactation stage-dependent expression of transporters in rat whole mammary gland and primary mammary epithelial organoids. Fundam Clin Pharmacol. 2010;24: 205–14.
- Halwachs S, Wassermann L, Lindner S, Zizzadoro C, Honscha W. Fungicide prochloraz and environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signalling pathway. Toxicol Sci. 2013;131:491–501.
- Halwachs S, Wassermann L, Honscha W. A novel MDCKII in vitro model for assessing ABCG2 transport activity in the caprine mammary gland by environmental pollutants and pesticides. Toxicol In Vitro. 2014;28:432–41.
- Jonker JW, Smit JW, Brinkhuis RF, Maliepard M, Beijnen JH, Schellens JH, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst. 2000;92:1651–6.
- Jonker JW, Merino G, Musters S, Herwaarden AE, Bolscher E, Wagenaar E, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med. 2005;11:127–9.
- Kabotyanski EB, Huetter M, Xian W, Rijnkels M, Rosen JM. Integration of prolactin and glucocorticoid signalling at the beta-casein promoter and enhancer by ordered recruitment of specific transcription factors and chromatin modifiers. Mol Endocrinol. 2006;20:2355–68.
- Kelleher SL, Lönnerdal B. Zip3 plays a major role in zinc uptake into mammary epithelial cells and is regulated by prolactin. Am J Physiol Cell Physiol. 2005;288:1042–7.
- Kelleher SL, Lönnerdal B. Mammary gland copper transport is stimulated by prolactin through alterations in Ctr1 and Atp7A localization. Am J Physiol Regul Integr Comp Physiol. 2006;291:1181–91.
- Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol and mitoxantrone. J Pharmacol Exp Ther. 2010;333:788–96.
- Krajci P. Drug-transporter interaction testing in drug discovery and development. World J Pharmacol. 2013;2:35–46.
- Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A, et al. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos. 2011;39:1196– 202.
- Lindner S, Halwachs S, Wassermann L, Honscha W. Expression and subcellular localization of efflux transporter ABCG2/ BCRP in important tissue barriers of lactating dairy cows, sheep and goats. J Vet Pharmacol Ther 2013;36-562-70
- Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001;61:3458– 64.
- Marte BM, Meyer T, Stabel S, Standke GIR, Jaken S, Fabbro D, et al. Protein kinase C and mammary cell differentiation: involvement of protein kinase C alpha in the induction of beta-casein expression. Cell Growth Differ. 1994;5:239–47.
- Matsson P, Englund G, Ahlin G, Bergström CAS, Norinder U, Artursson P. A global drug inhibiton pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther. 2007;323:19–30.

- McCormick NH, Kelleher SL. ZnT4 provides zinc to zincdependent proteins in the trans-Golgi network critical for cell function and Zn export in mammary epithelial cells. Am J Physiol Cell Physiol. 2012;303:291–7.
- McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, et al. A novel duodenal iron-regulated transporter, IREG, implicated in the basolateral transfer of iron to the circulation. Mol Cell. 2000;5:299–309.
- McManaman JL, Neville MC. Mammary physiology and milk secretion. Adv Drug Deliv Rev. 2003;55:629–41.
- Mealey KL. ABCG2 transporter: therapeutic and physiologic implications in veterinary species. J Vet Pharmacol Therap. 2012;35:105–12.
- Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoid on ABC transporters. Life Sci. 2006;78:2116-30.
- Öhrvik H, Oskarsson A, Lundh T, Skerfving S, Tallkvist J. Impact of iron status on cadmium uptake in suckling piglets. Toxicology. 2007;240:15–24.
- Öhrvik H, Ullerås E, Oskarsson A, Tallkvist J. Effects of cadmium on calcium transporter SPCA, calcium homeostasis and betacasein expression in the murine mammary epithelium. Toxicol Lett. 2010;201:80–5.
- Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, et al. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos. 2006;34:786–92.
- Real R, González-Lobato L, Baro MF, Valbuena S, de la Fuente A, Prieto JG, et al. Analysis of the effect of the bovine adenosine triphosphate-binding cassette transporter G2 single nucleotide polymorphism Y581S on transcellular transport of veterinary drugs using new cell culture models. J Anim Sci. 2011;89:4325–38.
- Richert MM, Schwertfeger KL, Ryder JW, Anderson SM. An atlas of mouse mammary gland development. J Mammary Gland Biol Neoplasia. 2000;5:227–41.

- Robinson GW, McKnight RA, Smith GH, Hennighausen L. Mammary epithelial cells undergo secretory differentiation in cycling virgins but require pregnancy for the establishment of terminal differentiation. Development. 1995;121:2079– 90.
- Ross DG, Smart CE, Azimi I, Roberts-Thomson SJ, Monteith GR. Assessment of ORAI1-mediated basal calcium influx in mammary epithelial cells. BMC Cell Biol. 2013;14:57. doi: 10.1186/1471-2121-14-57.
- van Herwaarden AE, Wagenaar E, Merino G, Jonker JW, Rosing H, Beijnen JH, et al. Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B₂) into milk. Mol Cell Biol. 2007;27:1247–53.
- Vlaming MLH, Lagas JS, Schinkel AH. Physiological and pharmacological roles of ABCG2(BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev. 2009;61:14–25.
- Wartmann M, Cella N, Hofer P, Groner B, Liu X, Hennighausen L, et al. Lactogenic hormone activation of Stat5 and transcription of the beta-casein gene in mammary epithelial cells is independent of p42 ERK mitogen-activated protein kinase activity. J Biol Chem. 1996;271:31863–8.
- Wassermann L, Halwachs S, Baumann D, Schaefer I, Seibel P, Honscha W. Assessment of ABCG2-mediated transport of xenobiotics across the blood-milk barrier of dairy animals using a new MDCKII in vitro model. Arch Toxicol. 2013;87: 1671–82.
- Wolf FI, Trapani V, Simonacci M, Mastrototaro L, Cittadini A, Schweigel M. Modulation of TRPM6 and Na(+)/Mg(2+) exchange in mammary epithelial cells in response to variations of magnesium availability. J Cell Physiol. 2010;222: 374–81.
- Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistence protein (ABCG2)-mediated transport. Mol Pharmacol. 2004;65:1208–16.